Because EVA1 is not expressed in normal cells, there may be less toxicity when targeting it to eliminate glioblastoma-initiating cells.

Che-Kai Tsao, MD, MS, discusses the current state of treatment for metastatic hormone-sensitive prostate cancer.

In an interview with Targeted Oncology, David J. Benjamin, MD, discussed findings on the global oncology workforce and their implications of insufficient access to cancer care.

A first-in-human phase 1/2 trial is evaluating the theranostic pair of ITM-91 and ITM-94 in patients with solid tumors.

Tafasitamab plus lenalidomide/rituximab cut progression risk by over 50% in relapsed follicular lymphoma, supporting its approval as a key second-line option.

Gregory J. Riely, MD, PhD, discusses targeted approaches for BRAF V600E, MET exon 14, and KRAS G12C mutations in metastatic NSCLC.

A novel immune-based therapy shows 100% response rates in newly diagnosed multiple myeloma patients, highlighting its potential as a frontline treatment.

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss the implications of findings from the phase 2 EDGE-Gastric trial.

Neladalkib elicited responses and was active in the CNS in TKI-pretreated patients with advanced ALK-positive NSCLC, including lorlatinib-naive patients.

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss current treatment standards in advanced gastric/GEJ cancer.

Zanidatamab plus chemotherapy shows significant survival benefits for HER2-positive gastroesophageal adenocarcinoma, potentially transforming first-line treatment options.

Zanidatamab-based regimens improved PFS and OS vs chemotherapy in HER2+ gastroesophageal adenocarcinoma, positioning the agent as a potential new standard.

Research highlights promising advancements in renal cell carcinoma treatments, focusing on HIF-2α inhibitors and combination therapies for improved patient outcomes.

Roswell Park Comprehensive Cancer Center is pleased to announce the recent accreditation of its rectal cancer program by the National Accreditation Program for Rectal Cancer.

Benjamin P. Levy, MD leads a live CFS discussion with Kamel Abou Hussein, MD and Victoria Rizk, MD on the evolving therapeutic landscape in breast cancer.

The safety profile of zanidatamab plus chemotherapy with or without tislelizumab was consistent with the known profiles of each individual agent.

At the 43rd Annual CFS meeting, John Allan, MD, highlighted ongoing efforts to advance the treatment paradigm for chronic lymphocytic leukemia.

PanTRKare was approved in China as a companion diagnostic to identify patients with NTRK fusion–positive solid tumors who may be eligible for entrectinib.

Sonia Jain, PhD, stated that depatuxizumab mafodotin, ABBV-221, and ABBV-321 were 3 of the most prominent ADCs in EGFR-amplified glioblastoma.

Biomarker testing in non-small cell lung cancer evolves with new protein-based markers and AI, enhancing personalized treatment strategies for patients.

The FDA has granted fast track designation to 4A10 for relapsed/refractory ALL.

Avelumab shows modest, durable responses in advanced penile cancer, highlighting the need for innovative treatments in this challenging patient population.

Panelists discuss how emerging therapies and biomarker-driven research are shaping the next wave of innovation in endometrial cancer treatment.

Panelists discuss how next-generation FGFR2b-targeted agents are advancing the field through innovative molecular engineering and delivery mechanisms.

Panelists discuss how daratumumab plus KRd demonstrates manageable toxicity and strong real-world feasibility with appropriate supportive care.

Panelists discuss how firmonertinib shows promise as a next-generation TKI with broad EGFR activity and favorable tolerability.

Panelists discuss how ADVANCE findings support the use of quadruplet therapy in both transplant-eligible and -ineligible patients with NDMM.

OncLive has launched a new podcast series, From Discovery to Delivery: Charting Progress in Gynecologic Oncology, hosted by Ursula A. Matulonis, MD.

Panelists discuss how ongoing phase 3 investigations are designed to confirm the efficacy and safety of FGFR2b-directed therapy in a broader patient population.

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.